Cellebrite Di Ltd SEC Filings

Form 144 notice for CLBTW reports a proposed sale of 44,623 common shares with an aggregate market value of $722,768.43. The sale is noted as approximately on 08/27/2025 on NASDAQ. The filer documents acquisition details showing restricted stock grants on 02/14/2024 (22,003 shares), 05/14/2024 (5,497 shares) and 08/14/2025 (2,110 shares), plus a stock option exercise on 08/27/2025 for 15,013 shares paid in cash. The notice also lists two recent sales by the same person during the prior three months: 10,281 shares on 08/26/2025 for $164,651.09 and 37,965 shares on 08/25/2025 for $608,243.82. The filer attests there is no undisclosed material adverse information and follows Rule 144 disclosure requirements.

Form 144 notice for CLBTW (Cellebrite DI Ltd.) shows a proposed public sale of 10,281 common shares through Morgan Stanley Smith Barney (NASDAQ) with an aggregate market value of $164,651.09 and an approximate sale date of 08/26/2025. The filer reports acquiring 4,984 shares by stock option exercise on 08/26/2025 (paid in cash) and restricted stock grants of 3,387 shares on 08/14/2025 and 1,910 shares on 08/14/2024. The filing also discloses a prior sale on 08/25/2025 of 37,965 shares for gross proceeds of $608,243.82 by Zohar Tadmor. The notice includes the signers representation that no undisclosed material adverse information is known.

Cellebrite DI Ltd. (CLBTW) Form 144 notifies the market of a proposed sale of 37,965 common shares through Morgan Stanley Smith Barney LLC on 08/25/2025. The filing reports an aggregate market value of $608,243.80 for the shares and shows 244,469,106 shares outstanding for the issuer. Acquisition details in the form indicate the shares were obtained as restricted stock on 08/14/2024, 11/14/2024, 02/14/2025, and 05/14/2025 (amounts 3,587; 5,497; 5,497; 5,497 respectively) and via a stock option exercise on 08/25/2025 (17,887 shares, paid in cash). The filer reports no securities sold in the past three months. The notice includes the standard representation that the person signing does not possess undisclosed material adverse information about the issuer.

Cellebrite DI Ltd. (CLBTW) reported a proposed sale of 2,799 common shares through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $44,532.09, and notes the securities were acquired as Restricted Stock Units on 08/20/2025. The filing shows recent dispositions by the same person: a sale of 2,874 shares on 08/21/2025 for $44,489.52 and a 10b5-1 plan sale of 12,150 shares on 05/23/2025 for $207,980.06. The filer certifies no undisclosed material adverse information and, where applicable, indicates reliance on a written 10b5-1 plan or trading instructions. This notice documents the planned transaction, the acquisition as RSUs, broker details, shares outstanding (244,469,106) and provides transparency about recent insider sales.

Cellebrite DI Ltd. Form 144 notice reports a proposed sale of 2,874 ordinary shares on 08/21/2025 through Morgan Stanley Smith Barney LLC on Nasdaq, with an aggregate market value of $44,489.52. The filer states there are 245,155,280 shares outstanding. The shares to be sold were partly acquired as 5,673 non-qualified performance stock units granted under an issuer S-8 plan on 08/20/2025, paid as employee compensation. The filing also discloses two prior sales by David Gee in May 2025 totaling 22,705 shares for gross proceeds of $381,590.05. The notice includes the standard certification that the seller does not possess undisclosed material adverse information.

Form 144 notice for CLBTW (Cellebrite DI Ltd.) discloses a proposed sale of 2,814 common shares, with an aggregate market value of $44,461.20, to be executed on 08/20/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The filing shows the shares were acquired by the reporting person from the issuer as follows: 1,087 shares via exercise of stock options on 08/20/2025 with cash payment, and 1,727 shares delivered as restricted stock units on 08/06/2025. The filing reports 244,469,106 shares outstanding for the class and indicates no securities sold in the past three months by the reporting person.

Form 144 notice for Cellebrite DI Ltd. (CLBTW) reports a proposed sale of 11,000 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $169,665.10 and approximately 239,470,062 shares outstanding. The filing shows the shares were originally acquired as restricted stock from the issuer on three dates: 5,826 shares on 08/31/2023, 3,768 shares on 07/18/2023, and 1,406 shares on 07/06/2024, and no sales by the filer in the past three months were reported.

The filer certifies they are not aware of undisclosed material adverse information about the issuer. The notice is procedural under Rule 144 to disclose an intended sale and does not include transaction proceeds, planned sale method beyond the broker, or additional contextual corporate details.

Cellebrite DI Ltd. (CLBTW) Form 144 summary: An individual filed a notice to sell 7,867 common shares through Morgan Stanley Smith Barney LLC on 08/19/2025, with an aggregate market value of $127,130.72. The filing reports the shares were acquired as Restricted Stock Units from the issuer on 08/15/2025 and paid on 08/15/2025. The filing also discloses a prior sale by Marcus H Jewell of 15,995 common shares on 08/18/2025 for $249,522.00. The notice states the signer represents no undisclosed material adverse information.

Form 144 filed for CLBTW: proposed sale of 15,995 ordinary shares on Nasdaq. The shares were acquired when 31,728 restricted share units vested under an S-8 plan on 08/15/2025 and were paid as employee compensation. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker and shows an aggregate market value of $249,522.00 for the proposed sale.

The filer previously sold 7,384 shares on 05/19/2025 for gross proceeds of $128,555.44. The filing includes the seller's representation that they are not aware of undisclosed material adverse information about the issuer.